Vascular calcification (VC) is common in dialysis and non-dialysis chronic kidney disease (CKD) patients, even in the early stage of the disease. For this reason, it can be considered a CKD hallmark. VC contributes to cardiovascular disease (CVD) and increased mortality among CKD patients, although it has not been proven. There are more than one type of VC and every form represents a marker of systemic vascular disease and is associated with a higher prevalence of CVD in CKD patients, as shown by several clinical studies. Major risk factors for VC in CKD include: Increasing age, dialysis vintage, hyperphosphatemia (particularly in the setting of intermittent or persistent hypercalcemia), and a positive net calcium and phosphate balance. Excessive oral calcium intake, including calcium-containing phosphate binders, increases the risk for VC. Moreover, it has been demonstrated that there is less VC progression with non-calcium-containing phosphate binders. Unfortunately, until now, a specific therapy to prevent progression or to facilitate regression of VC has been found, beyond careful attention to calcium and phosphate balance.

The key role of phosphate on vascular calcification / M. Cozzolino, P. Ciceri, A. Galassi, M. Mangano, S. Carugo, I. Capelli, G. Cianciolo. - In: TOXINS. - ISSN 2072-6651. - 11:4(2019 Apr 09), pp. 213.1-213.13. [10.3390/toxins11040213]

The key role of phosphate on vascular calcification

M. Cozzolino
Primo
;
P. Ciceri;M. Mangano;S. Carugo;
2019

Abstract

Vascular calcification (VC) is common in dialysis and non-dialysis chronic kidney disease (CKD) patients, even in the early stage of the disease. For this reason, it can be considered a CKD hallmark. VC contributes to cardiovascular disease (CVD) and increased mortality among CKD patients, although it has not been proven. There are more than one type of VC and every form represents a marker of systemic vascular disease and is associated with a higher prevalence of CVD in CKD patients, as shown by several clinical studies. Major risk factors for VC in CKD include: Increasing age, dialysis vintage, hyperphosphatemia (particularly in the setting of intermittent or persistent hypercalcemia), and a positive net calcium and phosphate balance. Excessive oral calcium intake, including calcium-containing phosphate binders, increases the risk for VC. Moreover, it has been demonstrated that there is less VC progression with non-calcium-containing phosphate binders. Unfortunately, until now, a specific therapy to prevent progression or to facilitate regression of VC has been found, beyond careful attention to calcium and phosphate balance.
hyperphosphatemia; chronic kidney disease; secondary hyperparathyroidism; vascular calcification; phosphate binder
Settore MED/14 - Nefrologia
9-apr-2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
toxins-11-00213.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 887.11 kB
Formato Adobe PDF
887.11 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/637694
Citazioni
  • ???jsp.display-item.citation.pmc??? 48
  • Scopus 109
  • ???jsp.display-item.citation.isi??? 97
social impact